The findings from this study are significant as they provide the first evidence supporting the use of olaparib in patients with newly diagnosed HRD-positive/BRCA wild-type ovarian cancer ...

HRD-positive tumours HRD (homologous recombination deficiency) is an important biomarker of the most advanced stages of ovarian cancer. It can be caused by different types of mutation, including ...

Opens in a new tab or window Homologous recombination deficiency (HRD) assays measure DNA damage repair dysfunction to identify patients with high-grade serous ovarian cancer (HGSOC) who may ...

The findings from this study are significant as they provide the first evidence supporting the use of olaparib in patients with newly diagnosed HRD-positive/BRCA wild-type ovarian cancer ...

Privately-held Austria firm pharmaand GmbH (pharma&) today announced that the National Institute of Health and Care Excellence (NICE) has issued a positive recommendation for its Rubraca (rucaparib).

Over 20% of high-grade serous ovarian cancer patients have BRCA mutations, and up to 50% exhibit HRD, impacting DNA repair pathways. Global guidelines recommend BRCA and HRD testing, but many ...

Patients with relapsed ovarian cancer who had germline or somatic BRCA mutations saw greater OS with olaparib, according to ...

on Tuesday announced positive preclinical data from a study evaluating its lead product, ERNA-101, for the treatment of ovarian cancer. ERNA-101, an innovative cell therapy, demonstrated ...

Roughly half of individuals with advanced ovarian cancer have an HRD-positive tumour, so the PAOLA-1 data should be promising for both clinicians and patients, offering the potential to give ...